Business Context and Reporting Period
Company: Tempus AI, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2025
Event: Entry into a Material Definitive Agreement (Third Amendment to Credit Agreement) to fund the acquisition of Ambry Genetics Corporation.
Key Financial Metrics and Debt Structure
This filing details a new debt facility rather than operational financial results (revenue, profit, or cash flow are not reported in this document).
- New Term Loan Facility: $200.0 million in senior secured term loans (Third Amendment Term Loans).
- New Revolving Facility: $100.0 million in priority revolving commitments (Priority ABL Facility).
- Funding Utilized: The Company borrowed the full $200.0 million in Term Loans and $100.0 million in Revolving Loans on the Closing Date.
- Maturity Dates:
- Third Amendment Term Loans and Priority ABL Facility: February 3, 2030.
- Existing Term Loans: September 2027.
- Interest Rates (Through Dec 31, 2025):
- Cash Interest: Base Rate + 6.25% or Term SOFR + 7.25%.
- PIK (Paid-in-Kind) Option: Base Rate + 4% or Term SOFR + 5%, plus a 3.25% PIK rate.
- Interest Rates (From Jan 1, 2026): Margins will vary based on leverage ratios and capital raising requirements (e.g., Term SOFR + 6.75% to 7.75% for cash interest).
- Revolving Loan Interest: Base Rate + 2.75% or Term SOFR + 3.75%.
- Commitment Fee: 0.50% per annum on unused revolving commitments (waived if Minimum Revolving Interest Amount applies).
Material Changes and Covenants
The primary material change is the expansion of the Company's debt capacity to finance the Ambry acquisition. The Credit Agreement includes the following covenants and restrictions:
- Financial Covenants: Minimum liquidity, minimum revenue, and a maximum first lien leverage ratio (effective from the fiscal quarter ending March 31, 2027).
- Restrictive Covenants: Limitations on incurring additional indebtedness, disposing of assets, incurring liens, making investments, and paying dividends or distributions.
- Security: Obligations are guaranteed by certain subsidiaries and secured by substantially all assets of the Company and such subsidiaries.
- Minimum Revolving Interest: Interest is payable as if the outstanding principal equaled the greater of 50% of Revolving Commitments or $50.0 million, if actual borrowings fall below this threshold.
Outlook, Risks, and Contingencies
Management Commentary: The debt amendment was executed specifically to fund the consideration payable for the acquisition of Ambry Genetics Corporation.
Risks: The agreement contains customary events of default, including payment defaults, breach of covenants, cross-acceleration to material indebtedness, bankruptcy, and change of control. An event of default allows lenders to terminate commitments and accelerate amounts due.
Contingencies: Future interest margins (post-January 2026) are contingent upon the Company's consolidated first lien leverage ratio and satisfaction of junior capital raising requirements.
Investor Verification Checklist
- Verify the total outstanding debt load post-closing, including the $300 million new borrowings and existing term loans maturing in 2027.
- Confirm the Company's ability to meet the "minimum revenue" and "minimum liquidity" covenants immediately following the acquisition.
- Assess the impact of the Paid-in-Kind (PIK) interest option on future cash flow and effective debt burden.
- Review the integration plan for Ambry Genetics to ensure the acquisition generates sufficient revenue to support the new leverage ratios required after March 31, 2027.
- Monitor the "Minimum Revolving Interest Amount" clause, which may result in interest payments on undrawn capacity.